FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282945237> ?p ?o ?g. }

• W4282945237 endingPage "5180" @default.
• W4282945237 startingPage "5180" @default.
• W4282945237 abstract "Abstract Background: The current first-line standard of care for recurrent or metastatic cervical cancer is platinum-based doublet chemotherapy ± bevacizumab, but its efficacy is limited. Immunotherapies with programmed cell death receptor-1 (PD-1) inhibitor or combination of PD-1 and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) inhibitors have been demonstrated to improve the clinical benefit for patients with recurrent or metastatic cervical cancer as second- or late-line treatment[1,2]. Their role in first-line treatment is under assessment. AK104 is a bispecific antibody (BsAb) that binds to both PD-1 and CTLA-4. This phase III trial aims to evaluate the efficacy and safety of AK104 plus standard chemotherapy with or without bevacizumab as first-line treatment for recurrent/metastatic cervical cancer. Trial Design: This phase III trial is a randomized, double-blind, placebo-controlled, multi-center study. Eligible patients are aged ≥ 18 and≤75 years, diagnosed with squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma of the cervix, not amenable to curative surgery or concurrent chemoradiotherapy, ECOG PS 0-1, and life expectancy ≥3 months. Patients will be excluded if they have prior systemic therapy for persistent, recurrent or metastatic disease, or have previously used anti-angiogenic therapy or immune therapy. Approximately 440 patients will be randomized (1:1) to AK104 + cisplatin/carboplatin+ paclitaxel± bevacizumab or placebo + cisplatin/carboplatin + paclitaxel ± bevacizumab. The treatment will be given every 3 weeks for up to 6 cycles, followed by maintenance therapy of AK104/placebo± bevacizumab until disease progression, intolerable toxicity, loss of clinical benefit as judged by the Investigator, withdrawal of consent, or completion of 2 years treatment of AK104/placebo. The primary endpoints are blinded independent central review (BICR)-assessed progression-free survival (PFS) and overall survival (OS). Second endpoints include Investigator-assessed PFS, BICR and Investigator-assessed Objective response rate (ORR), Disease control rate (DCR), Duration of response (DoR) and Time to response (TTR), and safety and tolerability for the treatment regime. The trial is currently enrolling patients. Clinical trial information: NCT04982237. Research Sponsor: Akeso Biopharma Co,. Ltd. Citation Format: Xiaohua Wu, Jing Wang, Yi Huang, Yuzhi Li, Yang Sun, Ke Wang, Michelle Xia, Baiyong Li, Wei Liu. A randomized, double-blind, placebo-controlled phase III study to evaluate AK104 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5180." @default.
• W4282945237 created "2022-06-16" @default.
• W4282945237 creator A5022189725 @default.
• W4282945237 creator A5026906414 @default.
• W4282945237 creator A5037677450 @default.
• W4282945237 creator A5055225807 @default.
• W4282945237 creator A5066041703 @default.
• W4282945237 creator A5071037763 @default.
• W4282945237 creator A5074582238 @default.
• W4282945237 creator A5075723177 @default.
• W4282945237 creator A5089296993 @default.
• W4282945237 date "2022-06-15" @default.
• W4282945237 modified "2023-10-07" @default.
• W4282945237 title "Abstract 5180: A randomized, double-blind, placebo-controlled phase III study to evaluate AK104 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer" @default.
• W4282945237 doi "https://doi.org/10.1158/1538-7445.am2022-5180" @default.
• W4282945237 hasPublicationYear "2022" @default.
• W4282945237 type Work @default.
• W4282945237 citedByCount "1" @default.
• W4282945237 countsByYear W42829452372022 @default.
• W4282945237 crossrefType "journal-article" @default.
• W4282945237 hasAuthorship W4282945237A5022189725 @default.
• W4282945237 hasAuthorship W4282945237A5026906414 @default.
• W4282945237 hasAuthorship W4282945237A5037677450 @default.
• W4282945237 hasAuthorship W4282945237A5055225807 @default.
• W4282945237 hasAuthorship W4282945237A5066041703 @default.
• W4282945237 hasAuthorship W4282945237A5071037763 @default.
• W4282945237 hasAuthorship W4282945237A5074582238 @default.
• W4282945237 hasAuthorship W4282945237A5075723177 @default.
• W4282945237 hasAuthorship W4282945237A5089296993 @default.
• W4282945237 hasConcept C121608353 @default.
• W4282945237 hasConcept C126322002 @default.
• W4282945237 hasConcept C141071460 @default.
• W4282945237 hasConcept C143998085 @default.
• W4282945237 hasConcept C2776694085 @default.
• W4282945237 hasConcept C2777802072 @default.
• W4282945237 hasConcept C2778220009 @default.
• W4282945237 hasConcept C2778239845 @default.
• W4282945237 hasConcept C2781451048 @default.
• W4282945237 hasConcept C71924100 @default.
• W4282945237 hasConceptScore W4282945237C121608353 @default.
• W4282945237 hasConceptScore W4282945237C126322002 @default.
• W4282945237 hasConceptScore W4282945237C141071460 @default.
• W4282945237 hasConceptScore W4282945237C143998085 @default.
• W4282945237 hasConceptScore W4282945237C2776694085 @default.
• W4282945237 hasConceptScore W4282945237C2777802072 @default.
• W4282945237 hasConceptScore W4282945237C2778220009 @default.
• W4282945237 hasConceptScore W4282945237C2778239845 @default.
• W4282945237 hasConceptScore W4282945237C2781451048 @default.
• W4282945237 hasConceptScore W4282945237C71924100 @default.
• W4282945237 hasIssue "12_Supplement" @default.
• W4282945237 hasLocation W42829452371 @default.
• W4282945237 hasOpenAccess W4282945237 @default.
• W4282945237 hasPrimaryLocation W42829452371 @default.
• W4282945237 hasRelatedWork W2003200862 @default.
• W4282945237 hasRelatedWork W2037317309 @default.
• W4282945237 hasRelatedWork W2051540233 @default.
• W4282945237 hasRelatedWork W2090201823 @default.
• W4282945237 hasRelatedWork W2091442233 @default.
• W4282945237 hasRelatedWork W2093727844 @default.
• W4282945237 hasRelatedWork W2352447425 @default.
• W4282945237 hasRelatedWork W2522002668 @default.
• W4282945237 hasRelatedWork W2733092439 @default.
• W4282945237 hasRelatedWork W3142026086 @default.
• W4282945237 hasVolume "82" @default.
• W4282945237 isParatext "false" @default.
• W4282945237 isRetracted "false" @default.
• W4282945237 workType "article" @default.